1. Home
  2. ESQ vs OMER Comparison

ESQ vs OMER Comparison

Compare ESQ & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESQ
  • OMER
  • Stock Information
  • Founded
  • ESQ 2006
  • OMER 1994
  • Country
  • ESQ United States
  • OMER United States
  • Employees
  • ESQ N/A
  • OMER N/A
  • Industry
  • ESQ Commercial Banks
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • ESQ Finance
  • OMER Health Care
  • Exchange
  • ESQ Nasdaq
  • OMER Nasdaq
  • Market Cap
  • ESQ 638.2M
  • OMER 530.2M
  • IPO Year
  • ESQ 2017
  • OMER 2009
  • Fundamental
  • Price
  • ESQ $85.68
  • OMER $9.13
  • Analyst Decision
  • ESQ Hold
  • OMER Buy
  • Analyst Count
  • ESQ 3
  • OMER 4
  • Target Price
  • ESQ $88.00
  • OMER $22.50
  • AVG Volume (30 Days)
  • ESQ 113.9K
  • OMER 509.4K
  • Earning Date
  • ESQ 01-23-2025
  • OMER 03-31-2025
  • Dividend Yield
  • ESQ 0.81%
  • OMER N/A
  • EPS Growth
  • ESQ 4.68
  • OMER N/A
  • EPS
  • ESQ 5.14
  • OMER N/A
  • Revenue
  • ESQ $120,124,000.00
  • OMER N/A
  • Revenue This Year
  • ESQ N/A
  • OMER N/A
  • Revenue Next Year
  • ESQ $10.75
  • OMER N/A
  • P/E Ratio
  • ESQ $16.70
  • OMER N/A
  • Revenue Growth
  • ESQ 10.21
  • OMER N/A
  • 52 Week Low
  • ESQ $44.45
  • OMER $2.61
  • 52 Week High
  • ESQ $90.18
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • ESQ 55.86
  • OMER 50.45
  • Support Level
  • ESQ $81.10
  • OMER $8.28
  • Resistance Level
  • ESQ $90.18
  • OMER $9.08
  • Average True Range (ATR)
  • ESQ 2.94
  • OMER 0.58
  • MACD
  • ESQ 0.09
  • OMER -0.05
  • Stochastic Oscillator
  • ESQ 60.95
  • OMER 62.58

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. The Bank operates a payment processing platform through third-party Independent Sales Organizations.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: